Literature DB >> 27799017

The Perceived Impact of 42 CFR Part 2 on Coordination and Integration of Care: A Qualitative Analysis.

Dennis McCarty1, Traci Rieckmann1, Robin L Baker1, K John McConnell1.   

Abstract

OBJECTIVE: Title 42 of the Code of Federal Regulations Part 2 (42 CFR Part 2) controls the release of patient information about treatment for substance use disorders. In 2016, the Substance Abuse and Mental Health Services Administration (SAMHSA) released a proposed rule to update the regulations, reduce provider burdens, and facilitate information exchange. Oregon's Medicaid program (Oregon Health Plan) altered the financing and structure of medical, dental, and behavioral care to promote greater integration and coordination. A qualitative analysis examined the perceived impact of 42 CFR Part 2 on care coordination and integration.
METHODS: Interviews with 76 stakeholders (114 interviews) conducted in 2012-2015 probed the processes of integrating behavioral health into primary care settings in Oregon and assessed issues associated with adherence to 42 CFR Part 2.
RESULTS: Respondents expressed concerns that the regulations caused legal confusion, inhibited communication and information sharing, and required updating. Addiction treatment directors noted the challenges of obtaining patient consent to share information with primary care providers.
CONCLUSIONS: The confidentiality regulations were perceived as a barrier to care coordination and integration. The Oregon Health Authority, therefore, requested regulatory changes. SAMHSA's proposed revisions permit a general consent to an entire health care team and allow inclusion of substance use disorder information within health information exchanges, but they mandate data segmentation of diagnostic and procedure codes related to substance use disorders and restrict access only to parties with authorized consent, possibly adding barriers to the coordination and integration of addiction treatment with primary care.

Entities:  

Keywords:  Addiction treatment; Alcohol use disorders; Confidentiality; Drug use disorders; Public policy issues

Mesh:

Year:  2016        PMID: 27799017      PMCID: PMC5441679          DOI: 10.1176/appi.ps.201600138

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  3 in total

Review 1.  A guiding framework and approach for implementation research in substance use disorders treatment.

Authors:  Laura J Damschroder; Hildi J Hagedorn
Journal:  Psychol Addict Behav       Date:  2011-06

2.  Oregon's Medicaid Transformation: An Innovative Approach To Holding A Health System Accountable For Spending Growth.

Authors:  K John McConnell; Anna Marie Chang; Deborah J Cohen; Neal Wallace; Michael E Chernew; Glenn Kautz; Dennis McCarty; Bentson McFarland; Bill Wright; Jeanene Smith
Journal:  Healthc (Amst)       Date:  2014-09

3.  Oregon's Medicaid Coordinated Care Organizations.

Authors:  K John McConnell
Journal:  JAMA       Date:  2016-03-01       Impact factor: 56.272

  3 in total
  13 in total

1.  Electronic Health Information Exchange At Discharge From Inpatient Psychiatric Care In Acute Care Hospitals.

Authors:  Morgan C Shields; Grant Ritter; Alisa B Busch
Journal:  Health Aff (Millwood)       Date:  2020-06       Impact factor: 6.301

2.  Interpretation and integration of the federal substance use privacy protection rule in integrated health systems: A qualitative analysis.

Authors:  Aimee N C Campbell; Dennis McCarty; Traci Rieckmann; Jennifer McNeely; John Rotrosen; Li-Tzy Wu; Gavin Bart
Journal:  J Subst Abuse Treat       Date:  2018-11-19

3.  Legislative and Policy Developments and Imperatives for Advancing the Primary Care Behavioral Health (PCBH) Model.

Authors:  Dennis S Freeman; Cathy Hudgins; Joel Hornberger
Journal:  J Clin Psychol Med Settings       Date:  2018-06

Review 4.  Is it feasible to pay specialty substance use disorder treatment programs based on patient outcomes?

Authors:  Dominic Hodgkin; Deborah W Garnick; Constance M Horgan; Alisa B Busch; Maureen T Stewart; Sharon Reif
Journal:  Drug Alcohol Depend       Date:  2019-11-14       Impact factor: 4.492

5.  Addressing Barriers to On-site HIV and HCV Testing Services in Methadone Maintenance Treatment Programs in the United States: Findings From a National Multisite Qualitative Study.

Authors:  Czarina N Behrends; Shashi N Kapadia; Bruce R Schackman; Jemima A Frimpong
Journal:  J Public Health Manag Pract       Date:  2021 Jul-Aug 01

Review 6.  America's opioid crisis: the need for an integrated public health approach.

Authors:  Carlos Blanco; Tisha R A Wiley; Jacqueline J Lloyd; Marsha F Lopez; Nora D Volkow
Journal:  Transl Psychiatry       Date:  2020-05-28       Impact factor: 6.222

7.  Clinical Workflow and Substance Use Screening, Brief Intervention, and Referral to Treatment Data in the Electronic Health Records: A National Drug Abuse Treatment Clinical Trials Network Study.

Authors:  Li-Tzy Wu; Elizabeth H Payne; Kimberly Roseman; Carla Kingsbury; Ashley Case; Casey Nelson; Robert Lindblad
Journal:  EGEMS (Wash DC)       Date:  2019-08-01

8.  Behavioral Health Professionals' Perceptions on Patient-Controlled Granular Information Sharing (Part 1): Focus Group Study.

Authors:  Julia Ivanova; Tianyu Tang; Nassim Idouraine; Anita Murcko; Mary Jo Whitfield; Christy Dye; Darwyn Chern; Adela Grando
Journal:  JMIR Ment Health       Date:  2022-04-20

Review 9.  Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network.

Authors:  Thomas Soeiro; Clémence Lacroix; Vincent Pradel; Maryse Lapeyre-Mestre; Joëlle Micallef
Journal:  Front Psychiatry       Date:  2021-05-17       Impact factor: 4.157

Review 10.  Recommendations to Inform Substance Use Disorder Data Sharing Research: Scoping Review and Thematic Analysis.

Authors:  George Karway; Julia Ivanova; Anweysha Bhowmik; Anita Murcko; Michael Saks; Dennis McCarty; Aimee Campbell; Maria Adela Grando
Journal:  J Addict Med       Date:  2022 May-Jun 01       Impact factor: 4.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.